Susan Zolla-Pazner

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. pmc Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2
    Luzia M Mayr
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 8:e70859. 2013
  2. pmc The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies
    Maria J Duenas-Decamp
    Center for AIDS Research, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, MA 01605, USA
    Retrovirology 9:9. 2012
  3. pmc Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design
    Susan Zolla-Pazner
    Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York 10010, USA
    Nat Rev Immunol 10:527-35. 2010
  4. pmc Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer
    Liuzhe Li
    Department of Pathology, New York University School of Medicine, New York, NY, USA
    Hum Antibodies 21:65-73. 2012
  5. pmc Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies
    Timothy Cardozo
    New York University School of Medicine, Departments of Pharmacology, Pathology and Environmental Medicine, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 25:441-50. 2009
  6. pmc Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Virology 427:198-207. 2012
  7. pmc Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Mol Immunol 46:917-26. 2009
  8. doi request reprint Conserved structural elements in the V3 crown of HIV-1 gp120
    Xunqing Jiang
    Department of Biochemistry, New York University School of Medicine, New York, New York, USA
    Nat Struct Mol Biol 17:955-61. 2010
  9. pmc Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 6:e27780. 2011
  10. ncbi request reprint The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1
    Susan Zolla-Pazner
    Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 20:1254-8. 2004

Collaborators

Detail Information

Publications46

  1. pmc Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2
    Luzia M Mayr
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 8:e70859. 2013
    ....
  2. pmc The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies
    Maria J Duenas-Decamp
    Center for AIDS Research, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, MA 01605, USA
    Retrovirology 9:9. 2012
    ..We compared HIV-1 envelopes and corresponding mutants that carried blocked W100 pockets to evaluate whether other CD4bs mabs target this site...
  3. pmc Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design
    Susan Zolla-Pazner
    Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York 10010, USA
    Nat Rev Immunol 10:527-35. 2010
    ..Recombinant immunogens that include these features may provide the means to address the antigenic diversity of HIV-1 and induce protective antibodies that can prevent infection with HIV-1...
  4. pmc Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer
    Liuzhe Li
    Department of Pathology, New York University School of Medicine, New York, NY, USA
    Hum Antibodies 21:65-73. 2012
    ..One representative V3 mAb displayed very potent neutralizing activity to one of two viruses tested. This study shows the feasibility of utilizing a peptide tetramer to select epitope-specific B cells and produce mAbs...
  5. pmc Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies
    Timothy Cardozo
    New York University School of Medicine, Departments of Pharmacology, Pathology and Environmental Medicine, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 25:441-50. 2009
    ..More importantly, these calculations demonstrate that globally relevant, structurally conserved epitopes are present in the sequence variable V3 loop...
  6. pmc Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Virology 427:198-207. 2012
    ..The data suggest the presence of shared, conserved structural elements in the V2 loop, and these can be used in the design of vaccine immunogens inducing broadly reactive Abs with anti-viral activities...
  7. pmc Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Mol Immunol 46:917-26. 2009
    ..The preferential usage of selected Ig gene segments and the characteristic pattern of Ig gene usage by anti-V3 mAbs can be related to the conserved structure of the V3 region...
  8. doi request reprint Conserved structural elements in the V3 crown of HIV-1 gp120
    Xunqing Jiang
    Department of Biochemistry, New York University School of Medicine, New York, New York, USA
    Nat Struct Mol Biol 17:955-61. 2010
    ..As these regions are targeted by cross-clade neutralizing human antibodies, they provide a blueprint for the design of vaccine immunogens that could elicit broadly cross-reactive protective antibodies...
  9. pmc Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 6:e27780. 2011
    ..This will be useful information for designing vaccine immunogen inducing cross-neutralizing Abs...
  10. ncbi request reprint The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1
    Susan Zolla-Pazner
    Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 20:1254-8. 2004
    ..These data illuminate the structural basis for both the breadth and specificity of a broadly neutralizing human mAb and contribute to our understanding of the epitopes recognized by Abs that protect against infection with HIV-1...
  11. pmc Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    J Virol 80:6865-72. 2006
    ....
  12. pmc The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    J Virol 78:2394-404. 2004
    ....
  13. pmc Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA
    Susan Zolla-Pazner
    Veterans Affairs Medical Center, New York, NY, USA
    J Virol 85:9887-98. 2011
    ....
  14. ncbi request reprint Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies
    Arthur Nadas
    Institute of Environmental Medicine, New York University School of Medicine, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 20:55-65. 2004
    ....
  15. ncbi request reprint Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope
    Susan Zolla-Pazner
    New York Veterans Affairs Medical Center, New York, NY 10010, USA
    Virology 372:233-46. 2008
    ..Neutralizing activity was primarily due to V3-specific Abs. The results demonstrate that the immune response can be focused on a neutralizing epitope and show that the anti-V3 Abs induced recognize a diverse set of V3 loops...
  16. pmc Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10010, USA
    J Virol 79:5232-7. 2005
    ..The existence of such a unique MAb, which defines a complex epitope formed by a quaternary structure, suggests that there may be other new neutralizing HIV epitopes to target with vaccines...
  17. pmc Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120
    Brett Spurrier
    Department of Biochemistry, NYU School of Medicine, New York, NY 10016, USA
    Structure 19:691-9. 2011
    ..Structural modeling suggests a way to understand the configuration of QNEs and the antigen-antibody interaction for QNE mAbs. Our data will be useful in designing immunogens that may elicit potent neutralizing QNE Abs...
  18. pmc Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects
    Evgeny Shmelkov
    Department of Pharmacology, New York University School of Medicine NYUSoM, New York, New York, United States of America
    PLoS ONE 6:e27279. 2011
    ....
  19. pmc Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope
    Susan Zolla-Pazner
    New York University School of Medicine, 550 First Avenue, New York, NY, USA
    Virology 392:82-93. 2009
    ..Greater than 80% of the neutralizing Abs were specific for V3, showing that the immune response could be focused on a neutralizing epitope and that vaccine-induced anti-V3 Abs have cross-clade neutralizing activity...
  20. pmc Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins
    Tetsuya Kimura
    Department of Pathology, New York University School of Medicine, New York, NY 10010, USA
    Hum Antibodies 18:35-40. 2009
    ..The data provide further evidence for the existence of a unique quaternary epitope V2/V3 on the surface of unliganded virus...
  21. ncbi request reprint HIV infection in rural villages of Cameroon
    Phillipe Nyambi
    Department of Pathology, New York University School of Medicine, c o VA Medical Center, 423 E 23rd Street, Room 18124N, New York, NY 10010, USA
    J Acquir Immune Defic Syndr 31:506-13. 2002
    ..To evaluate HIV-1 antibody seroprevalence and risk factors for HIV seropositivity in rural areas of Cameroon...
  22. ncbi request reprint High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression
    Peter C Chien
    Department of Pathology, New York University School of Medicine, and Veterans Affairs New York Harbor Healthcare System, New York, New York, USA
    J Infect Dis 186:205-13. 2002
    ..These findings document a novel mechanism of HIV pathogenesis mediated by anti-gp120(CD4bd) Abs exhibiting suppressive activity on gp120 presentation...
  23. pmc Quantitative assessment of masking of neutralization epitopes in HIV-1
    Alpna Agarwal
    Department of Pharmacology, New York University School of Medicine, 550 First Avenue MSB 497, New York, NY 10016, USA
    Vaccine 29:6736-41. 2011
    ..These results have important implications for rational design of vaccines designed to induce neutralizing Abs by revealing epitopes that are minimally masked and maximally reactive with neutralizing Abs...
  24. pmc Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
    Catarina E Hioe
    Department of Pathology, New York University Langone School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e10254. 2010
    ..Despite this evidence of V3 conservation, the ability of anti-V3 Abs to neutralize a significant proportion of HIV-1 isolates from different subtypes (clades) has remained controversial...
  25. pmc Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop
    David Almond
    Department of Pharmacology, New York University School of Medicine NYUSoM, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 26:717-23. 2010
    ..From a structural point of view, there appears to be less diversity in this region of the HIV-1 "principle neutralizing domain" than previously appreciated...
  26. pmc Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens
    Valicia Burke
    Department of Biochemistry, New York University School of Medicine, New York, NY 10016, USA
    Structure 17:1538-46. 2009
    ....
  27. ncbi request reprint Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity
    Ping Zhong
    Department of Pathology adn New York University School of Medicine, New York, New York 10010, USA
    AIDS Res Hum Retroviruses 19:1167-78. 2003
    ..This study further reveals the complexity of HIV-1 infection in rural Cameron and points to the future of the global epidemic, which may be characterized by more genetically diverse viruses...
  28. pmc Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals
    Raiees Andrabi
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Virology 439:81-8. 2013
    ..These results suggest that clade C V3 is probably weakly immunogenic and that the V3 sequence of CRF02_AG viruses can serve as a plausible template for vaccine immunogen design...
  29. pmc Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes
    James Swetnam
    Department of Pharmacology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e15994. 2010
    ..Our results suggest one way to quantify and compare the magnitude of the conservation...
  30. pmc Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication
    Ekaterina Dadachova
    Albert Einstein College of Medicine, Bronx, New York, United States of America
    PLoS ONE 7:e31866. 2012
    ..Based on our earlier proof-of-principle results targeting HIV-1 infected cells with radiolabeled antibody (mAb) to gp41 viral antigen, we embarked on identifying a suitable candidate mAb for preclinical development...
  31. pmc Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV
    Brett Spurrier
    Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, New York, USA
    J Virol 88:4100-12. 2014
    ....
  32. pmc Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject
    Liuzhe Li
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 7:e39534. 2012
    ....
  33. ncbi request reprint Thermodynamic signatures of the antigen binding site of mAb 447-52D targeting the third variable region of HIV-1 gp120
    April Killikelly
    Departments of Biochemistry and Molecular Pharmacology and Department of Pathology, New York University School of Medicine, New York, New York 10016, United States
    Biochemistry 52:6249-57. 2013
    ..Interrogation of the thermodynamic signatures of residues at the antigen binding interface gives key insights into their contributions in the antigen-antibody interaction. ..
  34. ncbi request reprint Structural basis for coreceptor selectivity by the HIV type 1 V3 loop
    Timothy Cardozo
    Department of Pharmacology and New York University School of Medicine, New York, NY 10016, USA
    AIDS Res Hum Retroviruses 23:415-26. 2007
    ..The results have additional implications for the design of HIV therapeutics, vaccines, and strategies for monitoring disease progression...
  35. ncbi request reprint Infection with HIV type 1 group M non-B subtypes in individuals living in New York City
    Jacqueline M Achkar
    Department of Medicine, New York University School of Medicine, NY 10010, USA
    J Acquir Immune Defic Syndr 36:835-44. 2004
    ..To document infection with HIV type 1 (HIV-1) group M non-B subtypes in individuals living in New York City...
  36. pmc Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins
    Ekaterina Dadachova
    Albert Einstein College of Medicine, Bronx, New York, United States of America
    PLoS Med 3:e427. 2006
    ..The aim of this proof-of-principle study was to demonstrate the efficacy of a therapeutic strategy of targeting and eliminating HIV-1-infected cells with radiolabeled antibodies specific to viral proteins in vitro and in vivo...
  37. ncbi request reprint Improving on nature: focusing the immune response on the V3 loop
    Susan Zolla-Pazner
    Laboratory and Research Services, New York Veterans Affairs Medical Center and Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Hum Antibodies 14:69-72. 2005
    ..Current data, summarized here, support the hypothesis that the V3 region of gp120 can induce broadly-reactive, cross-neutralizing Abs and as such should constitute a prominent target of the immune response induced with an HIV vaccine...
  38. pmc Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial
    Susan Zolla-Pazner
    Research Service, Veterans Affairs Medical Center, New York, New York, United States of America
    PLoS ONE 8:e53629. 2013
    ....
  39. pmc Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    J Virol 76:9035-45. 2002
    ..These studies demonstrate that human MAbs to conformation-sensitive epitopes of V3 display cross-clade reactivity in both binding to native, intact virions and neutralization of primary isolates...
  40. pmc Immunoprophylaxis against mother-to-child transmission of HIV-1
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS Med 3:e259. 2006
  41. pmc Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies
    David Almond
    Department of Pharmacology, New York University School of Medicine NYSoM, New York, NY 10016, USA
    Adv Virol 2012:803535. 2012
    ..As antibodies to a variable loop were recently identified as an inverse correlate of risk for HIV infection, the structure-function relationships discussed in this study may have relevance to HIV vaccine research...
  42. ncbi request reprint Evidence for CD4-enchanced signaling through the chemokine receptor CCR5
    Robert Staudinger
    Veterans Affairs New York Harbor Healthcare System, New York, New York 10016, USA
    J Biol Chem 278:10389-92. 2003
    ..Although the precise physiological role of the CD4 effects on CCR5-mediated signaling remains unknown, one can speculate that the cross-talk is a component of mechanisms involved in the fine tuning of immune system cell responses...
  43. pmc Distinct sequence patterns characterize the V3 region of HIV type 1 gp120 from subtypes A and C
    Klara Felsovalyi
    Department of Pharmacology, New York University School of Medicine and the New York Veterans Affairs Medical Center, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 22:703-8. 2006
    ..This lowest limit was 10(16). Although theoretically a p-value cannot be equal to 0.0, the p-value for the comparisons in question can be intuitively considered to be extremely small, or approximately 0.0.)...
  44. ncbi request reprint Chronic lymphocytic leukemia with prostate infiltration mediated by specific clonal membrane-bound IgM
    Carol A Bogdan
    Medical Service, New York Harbor Healthcare System, New York 10010, USA
    Cancer Res 63:2067-71. 2003
    ....
  45. pmc Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection
    Susan Zolla-Pazner
    Department of Veterans Affairs New York Harbor Healthcare System, New York, New York, United States of America New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 9:e87572. 2014
    ..The V1V2 antigens provide a link between RV144 and upcoming HIV-1 vaccine trials, and identify reagents and methods for evaluating V1V2 Abs as possible correlates of protection against HIV-1 infection...
  46. ncbi request reprint HIV type 1 group M clades infecting subjects from rural villages in equatorial rain forests of Cameroon
    Ping Zhong
    Department of Pathology, New York University School of Medicine, New York, NY, USA
    J Acquir Immune Defic Syndr 31:495-505. 2002
    ....